A single dose of dapagliflozin, an SGLT-2 inhibitor, induces higher glycosuria in GCK- and HNF1A-MODY than in type 2 diabetes mellitus

AIMS: SGLT2 inhibitors are a new class of oral hypoglycemic agents used in type 2 diabetes (T2DM). Their effectiveness in maturity onset diabetes of the young (MODY) is unknown. We aimed to assess the response to a single dose of 10 mg dapagliflozin in patients with Hepatocyte Nuclear Factor 1 Alpha...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Endocrine
Autors principals: Hohendorff, J., Szopa, M., Skupien, J., Kapusta, M., Zapala, B., Platek, T., Mrozinska, S., Parpan, T., Glodzik, W., Ludwig-Galezowska, A., Kiec-Wilk, B., Klupa, T., Malecki, M. T.
Format: Artigo
Idioma:Inglês
Publicat: Springer US 2017
Matèries:
Original Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5511327/
https://ncbi.nlm.nih.gov/pubmed/28593615
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12020-017-1341-2
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars